Jefferies Financial Group Inc. Sells 109,490 Shares of Compass Pathways PLC Sponsored ADR $CMPS

Jefferies Financial Group Inc. decreased its position in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 11.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 884,903 shares of the company’s stock after selling 109,490 shares during the period. Jefferies Financial Group Inc. owned 0.64% of Compass Pathways worth $11,008,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of CMPS. Orbimed Advisors LLC purchased a new position in Compass Pathways in the first quarter valued at about $6,363,000. Affinity Asset Advisors LLC raised its stake in shares of Compass Pathways by 454.2% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company’s stock worth $6,130,000 after purchasing an additional 908,483 shares in the last quarter. Eversept Partners LP acquired a new stake in shares of Compass Pathways during the 1st quarter valued at about $3,749,000. CenterBook Partners LP lifted its holdings in shares of Compass Pathways by 454.1% during the 3rd quarter. CenterBook Partners LP now owns 695,943 shares of the company’s stock valued at $8,658,000 after buying an additional 570,349 shares during the last quarter. Finally, Eagle Health Investments LP lifted its holdings in shares of Compass Pathways by 35.6% during the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock valued at $11,394,000 after buying an additional 541,039 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Wall Street Zen raised Compass Pathways from a “strong sell” rating to a “sell” rating in a research note on Sunday. Jefferies Financial Group reiterated a “buy” rating on shares of Compass Pathways in a research note on Monday. BTIG Research restated a “buy” rating and set a $25.00 price target on shares of Compass Pathways in a research note on Tuesday, November 3rd. Royal Bank Of Canada restated an “outperform” rating on shares of Compass Pathways in a report on Wednesday, November 4th. Finally, Morgan Stanley raised their price target on shares of Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $23.14.

Top Compass Pathways Stories

Here are a few of the latest stories about CMPS:

• Positive Sentiment: HC Wainwright’s updated estimates project narrower losses: its FY2026 EPS forecast improved to ($1.40) from ($1.58), and its FY2027 forecast to ($1.17) from ($1.56). The firm also raised estimates across the reported quarters through 2027 and maintained its Buy rating. Better-than-previous forecasts may support investor sentiment, though the company is still expected to post losses. Compass Pathways analyst estimates
• Neutral Sentiment: Compass Pathways plans to attend the Jefferies Global Healthcare Conference on November 18–19, including a fireside chat and panel. The appearance could provide investor visibility, but the announcement did not disclose new company developments. Conference announcement

Compass Pathways Trading Up 0.5%

Shares of NASDAQ:CMPS opened at $9.30 on Thursday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.50 and a current ratio of 1.50. The stock’s 50-day moving average is $12.06 and its 200-day moving average is $10.44. The company has a market cap of $1.32 billion, a P/E ratio of -2.66 and a beta of 2.43. Compass Pathways PLC Sponsored ADR has a 52-week low of $4.88 and a 52-week high of $15.87.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.08. Equities research analysts predict that Compass Pathways PLC Sponsored ADR will post -0.78 earnings per share for the current year.

Compass Pathways Profile

Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.